ClinicalTrials.gg
CompletedNCT00637377VIEW 2Updated Dec 12, 2014Results posted

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)

A Phase 3 interventional study of Ranibizumab and Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) in Macular Degeneration, sponsored by Bayer. Completed at 189 sites in 26 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2014-12-12.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,240
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 67 studies testing aflibercept in Macular Degeneration — 3 open to participants now, 6 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
Largest of 67
1,240 · median 54
Started
2008
the only one that year
Phase 3
18 of 67
1 open now
Registered
5th of 67
by date
Lead sponsor
8 of 67
Bayer

Among the 67 studies testing aflibercept in Macular Degeneration, this one has the largest enrollment, is the only one that started in 2008, is one of 18 in phase 3, and was the 5th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 67 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

This study is a phase III, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in Europe, Asia, Japan, Australia and South America.

Read the detailed description

Data of this trial ("VIEW 2") was pooled with data of a sister trial ("VIEW 1", NCT00509795), and an integrated analyses of the combined data was performed.

03

Conditions studied

  • Macular Degeneration

Keywords

  • Eye diseases
  • Vision Impairment and Blindness
  • Eyes and Vision
  • Seniors
  • Neovascular Age-Related Macular Degeneration (AMD)
  • Retinal Disease
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed .
  • Men and women >/=50 years of age.
  • Active primary or recurrent subfoveal CNV lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by Fluorescein angiography (FA) in the study eye.
  • ETDRS Best-Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters.
  • Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures.
  • Able to read, (or, if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member) understand and willing to sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular AMD, except dietary supplements or vitamins.
  • Any prior or concomitant therapy with another agent to treat neovascular AMD in the study eye.
  • Any prior treatment with anti-VEGF agents in the study eye.
  • Total lesion size >12 disc areas (30.5 mm, including blood, scars and neovascularization) as assessed by FA in the study eye.
  • Subretinal hemorrhages that is either 50% or more of the total lesion area, or if the blood is under the fovea and is 1 or more disc areas in size in the study eye (if the blood is under the fovea, then the fovea must be surrounded by 270 degrees by visible CNV).
  • Scar or fibrosis making up >50% of the total lesion in the study eye.
  • Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
  • Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.
  • History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye.
  • Presence of other causes of CNV in the study eye.
  • Prior vitrectomy in the study eye.
  • History of retinal detachment or treatment or surgery for retinal detachment in the study eye.
  • Any history of macular hole of stage 2 and above in the study eye.
  • Any intraocular or periocular surgery within 3 months of Day 1 on the study eye, except lid surgery, which may not have taken place within 1 month of Day 1, as long as it is unlikely to interfere with the injection.
  • History or clinical evidence of diabetic retinopathy, diabetic macular edema or any retinal vascular disease other than AMD in either eye.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,240 participants (actual)

Study arms

  • Active comparator
    Ranibizumab 0.5mg Q4

    Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

    Drug: Ranibizumab

  • Experimental
    Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4

    Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

    Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

  • Experimental
    Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4

    Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

    Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

  • Experimental
    Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8

    Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

    Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

Interventions

  • Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

  • Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

  • Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

  • Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)

    Maintenance of vision was defined as a loss of \< 15 letters in the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score (defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

    Time frame: At week 52

Secondary outcomes

  1. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 52 - LOCF

    Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.

    Time frame: Baseline and at week 52

  2. Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF

    Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

    Time frame: At week 52

  3. Mean Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF

    The possible range of the NEI VFQ-25 total score is between 0 (worst possible) and 100 (best possible).

    Time frame: Baseline and at week 52

  4. Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 - LOCF

    CNV area values measured in square millimeters; lower values represent better outcomes.

    Time frame: Baseline and at week 52

07

Results

Posted Jan 23, 2012
Limitations and caveats
The conditional sequence of hypothesis testing had to stop after testing the first superiority hypothesis. Therefore, all further statistical tests are exploratory tests.

Participant flow

The study was conducted at 186 study centers in 26 countries. Recruitment period: 21 Apr 2008 - 4 Sep 2009.

Participant flow — Overall Study
MilestoneRanibizumab 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8
Started303313311313
Participants received treatment291309297307
Participants treated (fas)291309296306
Completed276281274284
Not completed27323729
Withdrew: Adverse event2689
Withdrew: Death1321
Withdrew: Lack of efficacy0011
Withdrew: Lost to follow-up4122
Withdrew: Protocol violation2110
Withdrew: Withdrawal by subject11151311
Withdrew: Other (no further information available)76105

Outcome measures

PrimaryPercentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)

Maintenance of vision was defined as a loss of \< 15 letters in the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score (defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

Time frame:
At week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)
Percentage of participantsRanibizumab 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8
Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)94.4295.6296.2795.56
Statistical analysis
  • Ranibizumab 0.5mg Q4 vs Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 · Risk difference (rd): -1.20 · 95% CI -4.86 to 2.46The difference is calculated as Ranibizumab minus Aflibercept. A negative value favors the Aflibercept 2mg Q4 group. As adjustment of multiple comparisons a conditional sequence of statistical hypotheses is used with alpha = 0.05.
  • Ranibizumab 0.5mg Q4 vs Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 · Risk difference (rd): -1.84 · 95% CI -5.40 to 1.71The difference is calculated as Ranibizumab minus Aflibercept. A negative value favors the Aflibercept 0.5mg Q4 group. As adjustment of multiple comparisons a conditional sequence of statistical hypotheses is used with alpha = 0.05.
  • Ranibizumab 0.5mg Q4 vs Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 · Risk difference (rd): -1.13 · 95% CI -4.81 to 2.55The difference is calculated as Ranibizumab minus Aflibercept. A negative value favors the Aflibercept 2mg Q8 group. As adjustment of multiple comparisons a conditional sequence of statistical hypotheses is used with alpha = 0.05.
SecondaryMean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 52 - LOCF

Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.

Time frame:
Baseline and at week 52
Reported as:
Mean · Letters correctly read
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 52 - LOCF
Letters correctly readRanibizumab 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 52 - LOCF9.4 ± 13.57.6 ± 12.69.7 ± 14.18.9 ± 14.4
Statistical analysis
  • Ranibizumab 0.5mg Q4 vs Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 · ANCOVA · p = 0.076 (as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.) · Differences in least squares means: -1.9484 · 95% CI -4.1009 to 0.2040The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors Aflibercept 2mg Q4.
  • Ranibizumab 0.5mg Q4 vs Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 · ANCOVA · p = 0.9555 (as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.) · Differences in least squares means: -0.0620 · 95% CI -2.2398 to 2.1158The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors Aflibercept 0.5mg Q4
  • Ranibizumab 0.5mg Q4 vs Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 · ANCOVA · p = 0.4131 (as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.) · Differences in least squares means: -0.9014 · 95% CI -3.0615 to 1.2587The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors the Aflibercept 2mg Q8 group
SecondaryPercentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF

Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

Time frame:
At week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF
Percentage of participantsRanibizumab 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8
Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF34.0229.4534.8031.37
Statistical analysis
  • Ranibizumab 0.5mg Q4 vs Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 · Chi-squared · p = 0.229 (as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.) · Risk difference (rd): -4.57 · 95% CI -12.02 to 2.88The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors the Aflibercept 2mg Q4 group
  • Ranibizumab 0.5mg Q4 vs Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 · Chi-squared · p = 0.843 (as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.) · Risk difference (rd): 0.78 · 95% CI -6.91 to 8.46The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors the Aflibercept 0.5mg Q4 group
  • Ranibizumab 0.5mg Q4 vs Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 · Chi-squared · p = 0.490 (as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.) · Risk difference (rd): -2.65 · 95% CI -10.18 to 4.88The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors the Aflibercept 2mg Q8 group
SecondaryMean Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF

The possible range of the NEI VFQ-25 total score is between 0 (worst possible) and 100 (best possible).

Time frame:
Baseline and at week 52
Reported as:
Mean · Scores on a scale
Mean Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF
Scores on a scaleRanibizumab 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8
Mean Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF6.3 ± 14.84.5 ± 15.05.1 ± 13.74.9 ± 14.7
Statistical analysis
  • Ranibizumab 0.5mg Q4 vs Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 · ANCOVA · p = 0.0097 (as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.) · Differences in least squares means: -2.7885 · 95% CI -4.9012 to -0.6757The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors Aflibercept 2mg Q4.
  • Ranibizumab 0.5mg Q4 vs Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 · ANCOVA · p = 0.3917 (as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.) · Differences in least squares means: -0.9320 · 95% CI -3.0658 to 1.2019The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors Aflibercept 0.5mg Q4.
  • Ranibizumab 0.5mg Q4 vs Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 · ANCOVA · p = 0.0717 (as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.) · Differences in least squares means: -1.9470 · 95% CI -4.0659 to 0.1718The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors Aflibercept 2mg Q8.
SecondaryMean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 - LOCF

CNV area values measured in square millimeters; lower values represent better outcomes.

Time frame:
Baseline and at week 52
Reported as:
Mean · mm^2
Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 - LOCF
mm^2Ranibizumab 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8
Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 - LOCF-4.16 ± 5.90-5.95 ± 6.12-4.24 ± 6.13-5.16 ± 5.87
Statistical analysis
  • Ranibizumab 0.5mg Q4 vs Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 · ANCOVA · p = 0.0038 (as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.) · Differences in least squares means: -1.180 · 95% CI -1.979 to -0.382The difference is calculated as Aflibercept minus Ranibizumab. A negative value favors Aflibercept 2mg Q4.
  • Ranibizumab 0.5mg Q4 vs Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 · ANCOVA · p = 0.6784 (as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.) · Differences in least squares means: 0.170 · 95% CI -0.632 to 0.972The difference is calculated as Aflibercept minus Ranibizumab. A negative value favors Aflibercept 0.5mg Q4.
  • Ranibizumab 0.5mg Q4 vs Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 · ANCOVA · p = 0.0727 (as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.) · Differences in least squares means: -0.733 · 95% CI -1.534 to 0.068The difference is calculated as Aflibercept minus Ranibizumab. A negative value favors Aflibercept 2mg Q8.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab 0.5mg Q4—65/291 (22.3%)254/291 (87.3%)
Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4—81/309 (26.2%)259/309 (83.8%)
Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4—72/297 (24.2%)251/297 (84.5%)
Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8—81/307 (26.4%)260/307 (84.7%)
Most frequent serious events
Showing 10 of 285
Most frequent serious events
EventRanibizumab 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8
Visual acuity reducedEye disorders3/2915/3091/2977/307
PneumoniaInfections and infestations1/2914/3092/2976/307
CataractEye disorders5/2914/3094/2974/307
Myocardial infarctionCardiac disorders4/2913/3093/2974/307
Retinal haemorrhageEye disorders4/2913/3094/2972/307
Retinal detachmentEye disorders3/2910/3091/2970/307
Chest painGeneral disorders3/2911/3091/2971/307
Upper limb fractureInjury, poisoning and procedural complications2/2911/3093/2970/307
OsteoarthritisMusculoskeletal and connective tissue disorders0/2910/3093/2971/307
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2910/3093/2971/307
Most frequent other events
Showing 10 of 34
Most frequent other events
EventRanibizumab 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8
Retinal haemorrhageEye disorders82/29184/30970/29782/307
Visual acuity reducedEye disorders46/29144/30955/29760/307
Macular degenerationEye disorders37/29135/30942/29751/307
Conjunctival haemorrhageEye disorders34/29133/30946/29735/307
HypertensionVascular disorders42/29141/30933/29734/307
NasopharyngitisInfections and infestations39/29125/30932/29726/307
Detachment of retinal pigment epitheliumEye disorders38/29137/30933/29731/307
Retinal oedemaEye disorders34/29132/30931/29740/307
Intraocular pressure increasedInvestigations37/29138/30924/29729/307
Age-related macular degenerationEye disorders26/29128/30926/29738/307

Baseline characteristics

Age, Continuous
Age, Continuous(years)Ranibizumab 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8Total
Mean73.0 ± 9.074.1 ± 8.574.7 ± 8.673.8 ± 8.673.9 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8Total
Female169176147175667
Male122133149131535
Ethnicity
Ethnicity(participants)Ranibizumab 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8Total
Not Hispanic or Latino239259241251990
Hispanic or Latino52505555212
Race
Race(participants)Ranibizumab 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8Total
White213226219217875
Black or African American10124
Asian60676169257
Missing1716151866
National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) total score
National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) total score(scores on a scale)Ranibizumab 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8Total
Mean72.90 ± 19.0970.27 ± 19.4174.04 ± 18.2271.30 ± 19.0672.10 ± 18.99
Area of Choroidal Neovascularization (CNV)
Area of Choroidal Neovascularization (CNV)(mm^2)Ranibizumab 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8Total
Mean7.59 ± 5.348.25 ± 5.777.70 ± 5.267.75 ± 5.527.83 ± 5.48
Baseline lesion type
Baseline lesion type(participants)Ranibizumab 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8Total
Predominantly classic70728088310
Minimally classic104112103106425
Occult116123113110462
Missing12025
Baseline total lesion size
Baseline total lesion size(mm^2)Ranibizumab 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8Total
Mean8.01 ± 5.748.72 ± 6.148.17 ± 5.518.22 ± 5.878.28 ± 5.82

1 further baseline measures are reported on the registry.

08

Study locations

189 sites
  • Buenos Aires, Ciudad Auton. de Buenos Aires C1015ABO, Argentina
  • Buenos Aires, Ciudad Auton. de Buenos Aires C1023AAQ, Argentina
  • Buenos Aires, Ciudad Auton. de Buenos Aires C1122AAI, Argentina
  • Buenos Aires, Ciudad Auton. de Buenos Aires C1181ACH, Argentina
  • Rosario, Santa Fe S2000ANJ, Argentina
  • Córdoba, X5000IIT, Argentina
  • Chatswood, New South Wales 2067, Australia
  • Sydney, New South Wales 2000, Australia
  • Westmead, New South Wales 2145, Australia
  • East Melbourne, Victoria 3002, Australia
  • Parkville, Victoria 3050, Australia
  • Nedlands, Western Australia 6009, Australia
  • Parramatta, 2150, Australia
  • Innsbruck, 6020, Austria
  • Linz, 4021, Austria
  • Wien, 1090, Austria
  • Liege, 4000, Belgium
  • Ribeirão Preto, Sao Paulo 14048-900, Brazil
  • São Paulo, Sao Paulo 05651-901, Brazil
  • Minas Gerais, 30150-270, Brazil
  • Sao Paulo, 04023-062, Brazil
  • Medellín, Antioquia, Colombia
  • Cali, Cauca, Colombia
  • Bogota, Distrito Capital de Bogotá, Colombia
  • Brno, 63400, Czech Republic
  • Olomouc, 77520, Czech Republic
  • Praha 10, 10034, Czech Republic
  • Praha 4, 14000, Czech Republic
  • Usti nad Labem, 401 13, Czech Republic
  • Paris, Cedex 12 75557, France
  • Nantes, Cedex 1 44093, France
  • Besancon, 25030, France
  • Bordeaux, 33000, France
  • Dijon, 21079, France
  • Lyon, 69003, France
  • Lyon, 69006, France
  • Marseille, 13008, France
  • Paris, 75010, France
  • Paris, 75015, France
  • Freiburg, Baden-Württemberg 79106, Germany
  • Heidelberg, Baden-Württemberg 69120, Germany
  • Tübingen, Baden-Württemberg 72076, Germany
  • München, Bayern 81675, Germany
  • Regensburg, Bayern 93053, Germany
  • Darmstadt, Hessen 64297, Germany
  • Aachen, Nordrhein-Westfalen 52074, Germany
  • Bonn, Nordrhein-Westfalen 53105, Germany
  • Essen, Nordrhein-Westfalen 45122, Germany
  • Köln, Nordrhein-Westfalen 50924, Germany
  • Münster, Nordrhein-Westfalen 48145, Germany
  • Ludwigshafen, Rheinland-Pfalz 67063, Germany
  • Mainz, Rheinland-Pfalz 55131, Germany
  • Homburg, Saarland 66421, Germany
  • Dresden, Sachsen 01307, Germany
  • Dresden, Sachsen 06067, Germany
  • Leipzig, Sachsen 04103, Germany
  • Kiel, Schleswig-Holstein 24105, Germany
  • Lübeck, Schleswig-Holstein 23538, Germany
  • Berlin, 12200, Germany
  • Hamburg, 20251, Germany
  • Budapest, 1083, Hungary
  • Budapest, 1106, Hungary
  • Budapest, 1133, Hungary
  • Veszprem, 8200, Hungary
  • Ahemedabad - 4, Gujrat 380009, India
  • Wadala, Mumbai, Maharashtra 400031, India
  • Chennai, Tamil Nadu 600 006, India
  • Coimbatore, Tamil Nadu 641014, India
  • Madurai, Tamil Nadu 625 020, India
  • Pondicherry, Tamil Nadu 600007, India
  • Bangalore, 560010, India
  • Chandigarh, 160012, India
  • Hyderabad, 500 034, India
  • Kerala, 683572, India
  • Kolkata, 700073, India
  • Mumbai, 400 050, India
  • New Delhi, 110002, India
  • New Delhi, 110029, India
  • Orissa, 751 024, India
  • Afula, Israel
  • Beer Sheva, Israel
  • Haifa, 34362, Israel
  • Jerusalem, 91120, Israel
  • Kfar Saba, Israel
  • Petach Tikva, 49100, Israel
  • Rehovot, 76100, Israel
  • Tel Aviv, 64239, Israel
  • Tel Hashomer, Israel
  • Zrifin, 70300, Israel
  • Ancona, 60126, Italy
  • Bari, 70124, Italy
  • Catania, 95123, Italy
  • Genova, 16132, Italy
  • Milano, 20122, Italy
  • Milano, 20132, Italy
  • Milano, 20157, Italy
  • Padova, 35128, Italy
  • Roma, 00133, Italy
  • Roma, 00168, Italy
  • Roma, 00198, Italy

Showing the first 100 of 189 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17. Erratum In: Ophthalmology. 2013 Jan;120(1):209-10. PubMed 23084240 ↗
  • Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014 Jan;121(1):193-201. doi: 10.1016/j.ophtha.2013.08.011. Epub 2013 Sep 29. PubMed 24084500 ↗
  • Moshfeghi DM, Thompson D, Saroj N. Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies. Br J Ophthalmol. 2020 Sep;104(9):1223-1227. doi: 10.1136/bjophthalmol-2019-315021. Epub 2019 Dec 11. PubMed 31826853 ↗
  • Yuzawa M, Fujita K, Wittrup-Jensen KU, Norenberg C, Zeitz O, Adachi K, Wang EC, Heier J, Kaiser P, Chong V, Korobelnik JF. Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration. Ophthalmology. 2015 Mar;122(3):571-8. doi: 10.1016/j.ophtha.2014.09.024. Epub 2014 Nov 6. PubMed 25439429 ↗
  • Ogura Y, Terasaki H, Gomi F, Yuzawa M, Iida T, Honda M, Nishijo K, Sowade O, Komori T, Schmidt-Erfurth U, Simader C, Chong V; VIEW 2 Investigators. Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. Br J Ophthalmol. 2015 Jan;99(1):92-7. doi: 10.1136/bjophthalmol-2014-305076. Epub 2014 Aug 8. PubMed 25107900 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Sep 2010 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2008
First posted
Mar 18, 2008
Start
Apr 2008
Primary completionActual
Sep 2010
CompletionActual
Aug 2011
Results first posted
Jan 23, 2012
Last update
Dec 12, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00637377
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Mar 18, 2008
Start date
Apr 2008
Primary completion
Sep 2010
Completion
Aug 2011
Results posted
Jan 23, 2012
Last update
Dec 12, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion